Summary
This conference abstract presents an application of high-dimensional mass cytometry and machine learning bioinformatics to profile immune responses in cancer patients receiving anti-PD-1 checkpoint inhibitor therapy. The authors argue that data-driven characterisation of immune cell phenotypes before and during treatment may enable earlier patient stratification and prediction of immunotherapy response, potentially improving clinical outcomes. The approach integrates single-cell protein expression data across multiple samples to identify biomarker signatures associated with therapeutic benefit.
UK applicability
The methodology could be applicable to UK cancer centres with access to advanced flow cytometry platforms and bioinformatics capacity, potentially supporting precision oncology initiatives within the NHS; however, clinical validation and cost-effectiveness assessment would be required before implementation in routine practice.
Key measures
Mass cytometry (CyTOF) quantification of 34 protein markers on single cells across 20 patient samples; machine learning classification of immune response patterns
Outcomes reported
The study characterised immune cell protein expression profiles in cancer patients before and during anti-PD-1 immunotherapy using high-dimensional mass cytometry combined with machine learning to identify biomarkers predictive of treatment response.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.